Reaction
Nuclear Magnetic Resonance Imaging Abnormal reporting signals
As of the last recalculation, Nuclear Magnetic Resonance Imaging Abnormal appears in 3,317 FAERS reports alongside 23 co-occurring drug terms. The strongest observed disproportionality signal is NATALIZUMAB (PRR 35.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Natalizumab | 789 | 35.4 | 35.6 |
| Alemtuzumab | 94 | 31.4 | 31.5 |
| Interferon Beta-1A | 747 | 31.0 | 31.1 |
| Glatiramer Acetate | 245 | 27.7 | 27.8 |
| Teriflunomide | 176 | 25.7 | 25.8 |
| Dimethyl Fumarate | 369 | 21.1 | 21.1 |
| Peginterferon Beta-1A | 33 | 15.9 | 16.0 |
| Interferon Beta-1B | 37 | 12.2 | 12.3 |
| Fingolimod Hcl | 90 | 6.7 | 6.7 |
| Amantadine | 16 | 6.5 | 6.5 |
| Dalfampridine | 72 | 6.4 | 6.4 |
| Amlodipine Besylate And Benazepril Hydrochloride | 9 | 6.1 | 6.1 |
| Zidovudine | 13 | 6.1 | 6.1 |
| Bupivacaine | 9 | 6.1 | 6.1 |
| Modafinil | 25 | 4.9 | 4.9 |
| Tizanidine Hydrochloride | 14 | 4.9 | 4.9 |
| Raloxifene Hydrochloride | 10 | 4.3 | 4.3 |
| Baclofen | 58 | 4.3 | 4.3 |
| Vigabatrin | 9 | 3.9 | 3.9 |
| Ocrelizumab | 37 | 3.8 | 3.8 |
| Temozolomide | 11 | 3.3 | 3.3 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 8 | 2.1 | 2.1 |
| Hydrocodone Bitartrate | 9 | 1.3 | 1.3 |